Anteris Technologies (ASX: $AVR) Fundraising Announcement

Anteris Technologies Ltd (ASX: $AVR) has successfully raised $23 million by placing one million new ordinary shares at $23 each. The funds will primarily be utilized for preparing for the DurAVRTM transcatheter heart valve's FDA pivotal study, a crucial step in obtaining regulatory clearance for the US market. Additionally, the funds will support strategic initiatives, valve-in-valve trials, and general working capital.

Executive Commentary on Fundraising and Utilization of Funds

The funds raised through the placement of new ordinary shares at $23 each will significantly contribute to advancing our DurAVRTM transcatheter heart valve's FDA pivotal study. This pivotal study is a key milestone in our journey towards gaining regulatory clearance for the US market, and we are committed to utilizing the funds effectively to achieve this goal. Furthermore, the support for strategic initiatives, valve-in-valve trials, and general working capital will strengthen our position in delivering transformative solutions to structural heart disease patients.

Summary of Anteris Technologies (ASX: $AVR) Fundraising Announcement

Anteris Technologies Ltd (ASX: $AVR) has successfully raised $23 million to primarily prepare for the DurAVRTM transcatheter heart valve's FDA pivotal study and to support strategic initiatives, valve-in-valve trials, and general working capital. The company's commitment to designing, developing, and commercializing innovative medical devices, particularly the DurAVRTM transcatheter heart valve, reflects its dedication to addressing significant unmet clinical needs in the structural heart market. The successful fundraising positions Anteris Technologies to advance its corporate strategy and achieve regulatory clearance for the US market, ultimately aiming to revolutionize the treatment of structural heart disease.